Company: PRME
Filing Date: 2025-11-07
Form Type: S-3ASR
Source: 0001628280-25-050428
Chunk: 53

Company: Prime Medicine, Inc.
Filing Date: 2025-11-07
Form: S-3ASR
Chunk 53
---
, but are not limited to, statements about:

• the initiation, timing, progress and results of our research and development programs, product candidates, preclinical studies and future clinical trials;

• our ability to demonstrate, and the timing of, preclinical proof-of-concept in vivo for multiple programs;

• our ability to advance any current or future product candidates that we may identify and successfully complete any clinical studies, including the manufacture of any such product candidates;

• our ability to pursue our areas of focus and any other additional programs we may advance;

• our ability to quickly leverage programs within our initial target indications and to progress additional programs to further develop our pipeline;

• the timing of our investigational new drug (“IND”) application submissions;

• the ability of our Prime Editing technology to address unmet medical needs in patients;

• the implementation of our strategic plans for our business, programs and technology;

• the scope and duration of protection we are able to establish and maintain for intellectual property rights covering our Prime Editing technology;

• developments related to our competitors and our industry;

• our ability to leverage the clinical, regulatory, and manufacturing advancements made by gene therapy and gene editing programs to accelerate our clinical trials and approval of product candidates;

• our ability to maintain existing collaborations or strategic relationships, to identify and enter into future license agreements and collaborations on favorable terms, if at all, and to realize the intended and potential benefits of such agreements and collaborations;

• developments related to our Prime Editing technology;

• regulatory developments in the United States and foreign countries;

• our ability to attract and retain key scientific and management personnel;

• the accuracy of our estimates regarding our expenses, capital requirements, and needs for additional financing;

• our anticipated use of net proceeds from offerings of shares of our common stock pursuant to this prospectus;

<div align='center'>S-iv</div>

• our expectations regarding the anticipated timeline of our cash runway and future financial performance;

• our evaluation of strategic alternatives and potential partnership opportunities for PM359, including our ability to execute and realize the anticipated benefits of any strategic alternatives we may pursue;

• our ability to maintain an effective system of internal controls;

• the effect of unfavorable macroeconomic conditions or market volatility resulting from national or global economic conditions or geopolitical developments, including rising inflation and capital market disruptions, changes in or disruptions of U.S. governmental agencies, whether from a continued U.S.